Cargando…

Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis

Allogeneic hematopoietic stem cell transplant remains the only curative treatment for myelofibrosis. Most post-transplantation events occur during the first two years and hence we aimed to analyze the outcome of 2-year disease-free survivors. A total of 1055 patients with myelofibrosis transplanted...

Descripción completa

Detalles Bibliográficos
Autores principales:	Robin, Marie, de Wreede, Liesbeth C., Wolschke, Christine, Schetelig, Johannes, Eikema, Diderik-Jan, Van Lint, Maria Teresa, Knelange, Nina Simone, Beelen, Dietrich, Brecht, Arne, Niederwieser, Dietger, Vitek, Antonin, Bethge, Wolfgang, Arnold, Renate, Finke, Jürgen, Volin, Liisa, Yakoub-Agha, Ibrahim, Nagler, Arnon, Poiré, Xavier, Einsele, Hermann, Chevallier, Patrice, Holler, Ernst, Ljungman, Per, Robinson, Stephen, Radujkovic, Alekxandar, McLornan, Donal, Chalandon, Yves, Kröger, Nicolaus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717573/ https://www.ncbi.nlm.nih.gov/pubmed/30733269 http://dx.doi.org/10.3324/haematol.2018.205211

Ejemplares similares

Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation
por: Gagelmann, Nico, et al.
Publicado: (2019)

Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia
por: Schetelig, Johannes, et al.
Publicado: (2018)

State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019
por: McLornan, Donal P., et al.
Publicado: (2019)

Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT
por: Cremers, E. M. P., et al.
Publicado: (2016)

Competing-risk outcomes after hematopoietic stem cell transplantation from the perspective of time-dependent effects
por: Fuerst, Daniel, et al.
Publicado: (2018)

Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation
por: Schmid, Christoph, et al.
Publicado: (2018)

Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: a study from the Acute Leukemia Working Party of the EBMT
por: Poiré, Xavier, et al.
Publicado: (2020)

Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
por: Saraceni, Francesco, et al.
Publicado: (2019)

Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosis
por: Robin, Marie, et al.
Publicado: (2019)

The Chinese HCT survey: a non-manipulated haploidentical transplantation procedure makes a novel contribution to data sharing within the regional and global transplant registries and to worldwide knowledge
por: Niederwieser, Dietger
Publicado: (2021)

Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT
por: Santoro, Nicole, et al.
Publicado: (2018)

Combination therapies in Myeloproliferative Neoplasms: why do we need them and how to identify potential winners?
por: McLornan, Donal, et al.
Publicado: (2013)

Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT
por: Kröger, Nicolaus, et al.
Publicado: (2021)

Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study
por: Greinix, Hildegard T., et al.
Publicado: (2021)

Intravesical recurrence of chromophobe renal cell carcinoma
por: Kelly, Niall P., et al.
Publicado: (2023)

Biosimilar agents in oncology/haematology: from approval to practice
por: Niederwieser, Dietger, et al.
Publicado: (2011)

Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation
por: Shimoni, Avichai, et al.
Publicado: (2016)

Urosepsis and the urologist!
por: Ryan, James, et al.
Publicado: (2021)

JAK2 V617F: A Single Mutation in the Myeloproliferative Group of Disorders
por: McLornan, Donal, et al.
Publicado: (2006)

Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date
por: Bassiony, Sarah, et al.
Publicado: (2020)

Bone marrow niche dysregulation in myeloproliferative neoplasms
por: Curto-Garcia, Natalia, et al.
Publicado: (2020)

Implementation of telemedicine in response to COVID-19 in a Dublin hospital - A patient perspective
por: Horan, M., et al.
Publicado: (2021)

Primary Cancer Matters in Therapy-related Myeloid Neoplasm Patients Receiving Allogeneic Hematopoietic Cell Transplantation: A Study From the Chronic Malignancies Working Party of the EBMT
por: Robin, Marie, et al.
Publicado: (2023)

Handling of Allogeneic HPC Grafts in European Transplant Centers during the COVID-19 Pandemic - a Survey from the Infectious Diseases and Cellular Therapy & Immunobiology Working Parties of the EBMT
por: Worel, Nina, et al.
Publicado: (2022)

The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years—a report from the EBMT acute leukemia working party
por: Rubio, Marie T., et al.
Publicado: (2016)

The activities and regulatory landscape of cellular therapies including hematopoietic cell transplantation in the world
por: Okamoto, Shinichiro, et al.
Publicado: (2022)

Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study
por: Schetelig, Johannes, et al.
Publicado: (2020)

Correction to: Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: results of a prospective observational study
por: Schetelig, Johannes, et al.
Publicado: (2021)

Impact of Donor Activating KIR Genes on HSCT Outcome in C1-Ligand Negative Myeloid Disease Patients Transplanted with Unrelated Donors—A Retrospective Study
por: Neuchel, Christine, et al.
Publicado: (2017)

Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT
por: Gilleece, Maria H., et al.
Publicado: (2021)

Ruxolitinib for the Treatment of Essential Thrombocythemia
por: Gunawan, Arief, et al.
Publicado: (2018)

Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party
por: Hayden, Patrick J., et al.
Publicado: (2021)

Economics and Outcome After Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study
por: Gratwohl, Alois, et al.
Publicado: (2015)

The European landscape on allogeneic haematopoeietic cell transplantation in Chronic Lymphocytic Leukaemia between 2009 and 2019: a perspective from the Chronic Malignancies Working Party of the EBMT
por: Tournilhac, Olivier, et al.
Publicado: (2023)

Internet-based grief therapy for bereaved individuals after loss due to Haematological cancer: study protocol of a randomized controlled trial
por: Hoffmann, Rahel, et al.
Publicado: (2018)

Multiple imputation for cause-specific Cox models: Assessing methods for estimation and prediction
por: Bonneville, Edouard F, et al.
Publicado: (2022)

Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT
por: Tilmont, Rémi, et al.
Publicado: (2023)

The impact of COVID-19 on acute urinary stone presentations: a single-centre experience
por: Anderson, Steven, et al.
Publicado: (2021)

Advantages of a multi-state approach in surgical research: how intermediate events and risk factor profile affect the prognosis of a patient with locally advanced rectal cancer
por: Manzini, G., et al.
Publicado: (2018)

Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party
por: Scheid, C, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_tmq01ceqo1q8nuc1i84io3darl